1. Medtech Insight

ADA2018: Senseonics' Implantable CGM Beats Abbott, Dexcom In Head-To-Head Study – But Is Methodology Flawed?

 
• By Marion Webb

In a three-way patient study comparing the accuracy of three currently available continuous glucose monitoring (CGM) devices, the newly FDA-approved Eversense by Senseonics performed significantly better than the Abbott Freestyle Libre Pro and Dexcom G5. The study findings were presented during this year's annual American Diabetes Association meeting in Orlando, Florida. This article also discusses other highlights presented by the three companies at the ADA conference.

Diabetes equipment set. Glucose meter. Glucose blood test. Diabetes equipment, Insulin pen. Insulin Pumps. Bloodless glucometer. Continuous Glucose Monitoring. Portable Glucometer on white background

In a head-to-head study comparing the accuracy of three available continuous glucose monitoring (CGM) devices – Dexcom Inc.'s G5 (not the newly licensed G6), Abbott Diabetes Care Inc.'s Freestyle Libre Pro (not the patient version) and Senseonics Holdings Inc.' Eversense, an implantable device – in a real world outpatient setting, the point accuracy of the Eversense CGM system was significantly better than the other two systems, Rabab Jafri of Massachusetts General Hospital, Boston wrote in the July issue of the American Diabetes Association's medical journal Diabetes.

Findings of the study involving 23 adults with type 1 diabetes, who wore all three devices concomitantly at home for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By Marion Webb

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By Ashley Yeo

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.